Bayer secures approval in EU for Xarelto for patients with coronary or peripheral artery disease
The EU approval is based on data from the COMPASS study, the largest phase III study with rivaroxaban (27,395 patients), which showed that the rivaroxaban vascular dose, 2.5mg